Our findings demonstrate that PLOD1, PLOD2, and PLOD3 are consistently upregulated in ccRCC tissues and correlate with poor clinical outcomes, including reduced OS and DFS. The gene discussed is PLOD2; the disease is nonpapillary renal cell carcinoma.